Leflunomide Cf

Leflunomide, the active ingredient in Leflunomide Cf, is an immunosuppressant presented as an oral formulation for systemic use. It is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis in adult and pediatric patients where disease‑modifying therapy is required.

GNH USA supplies Leflunomide Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Leflunomide is used to modify disease activity in inflammatory arthritis conditions by reducing immune‑mediated joint damage.

- Rheumatoid arthritis: reduces joint inflammation and slows structural damage, improving functional ability. - Psoriatic arthritis: alleviates skin and joint symptoms, decreasing disease progression. - Juvenile idiopathic arthritis: controls systemic inflammation and joint involvement in pediatric patients.

Leflunomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: loose stools often occurring early in therapy. - Nausea: feeling of sickness that may improve over time. - Elevated liver enzymes: mild increases in ALT or AST. - Hypertension: rise in blood pressure requiring monitoring.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatic failure, or hepatitis. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Interstitial lung disease: cough, dyspnea, and pulmonary infiltrates.

When prescribing Leflunomide, clinicians should observe several safety precautions to minimize risk.

- Monitor liver function: obtain baseline tests and repeat periodically. - Check blood pressure: measure regularly during treatment. - Assess for infections: evaluate signs of opportunistic or severe infections. - Avoid use in pregnancy: contraindicated due to teratogenic risk. - Store at room temperature: keep in original packaging, protect from moisture and heat.

Leflunomide interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Methotrexate: increased hepatotoxicity risk. - Warfarin: enhanced anticoagulant effect, may raise INR. - Live vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone marrow suppression. - Cyclosporine: possible increased plasma levels of both agents. - TNF‑α inhibitors: may augment immunosuppressive effects.